Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/57330
Type
ArticleCopyright
Open access
Sustainable Development Goals
03 Saúde e Bem-EstarCollections
Metadata
Show full item record
PLASMODIUM VIVAX VACCINE: WHAT IS THE BEST WAY TO GO?
Author
Affilliation
Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Pesquisa em Apicomplexa. Curitiba, PR, Brasil. / Universidade Federal do Paraná. Departamento de Bioquímica e Biologia Molecular. Laboratório de Fixação de Nitrogênio. Curitiba, PR, Brasil.
União Educacional de Cascavel (UNIVEL). Curso de Biomedicina. Cascavel, PR, Brasil.
União Educacional de Cascavel (UNIVEL). Curso de Biomedicina. Cascavel, PR, Brasil.
Universidade Federal do Paraná. Departamento de Bioquímica e Biologia Molecular. Laboratório de Fixação de Nitrogênio. Curitiba, PR, Brasil.
Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Pesquisa em Apicomplexa. Curitiba, PR, Brasil.
União Educacional de Cascavel (UNIVEL). Curso de Biomedicina. Cascavel, PR, Brasil.
União Educacional de Cascavel (UNIVEL). Curso de Biomedicina. Cascavel, PR, Brasil.
Universidade Federal do Paraná. Departamento de Bioquímica e Biologia Molecular. Laboratório de Fixação de Nitrogênio. Curitiba, PR, Brasil.
Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Pesquisa em Apicomplexa. Curitiba, PR, Brasil.
Abstract
Malaria is one of the most devastating human infectious diseases caused by Plasmodium spp. parasites. A search for an effective and safe vaccine is the main challenge for its eradication. Plasmodium vivax is the second most prevalent Plasmodium species and the most geographically distributed parasite and has been neglected for decades. This has a massive gap in knowledge and consequently in the development of vaccines. The most significant difficulties in obtaining a vaccine against P. vivax are the high genetic diversity and the extremely complex life cycle. Due to its complexity, studies have evaluated P. vivax antigens from different stages as potential targets for an effective vaccine. Therefore, the main vaccine candidates are grouped into preerythrocytic stage vaccines, blood-stage vaccines, and transmission-blocking vaccines. This review aims to support future investigations by presenting the main findings of vivax malaria vaccines to date. There are only a few P. vivax vaccines in clinical trials, and thus far, the best protective efficacy was a vaccine formulated with synthetic peptide from a circumsporozoite protein and Montanide ISA-51 as an adjuvant with 54.5% efficacy in a phase IIa study. In addition, the majority of P. vivax antigen candidates are polymorphic, induce strain-specific and heterogeneous immunity and provide only partial protection. Nevertheless, immunization with recombinant proteins and multiantigen vaccines have shown promising results and have emerged as excellent strategies. However, more studies are necessary to assess the ideal vaccine combination and test it in clinical trials. Developing a safe and effective vaccine against vivax malaria is essential for controlling and eliminating the disease. Therefore, it is necessary to determine what is already known to propose and identify new candidates.
Share